ArticleCureus2025
Kienböck's Disease in a Patient With Cerebral Palsy: Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kienböck's disease is a rare condition characterized by avascular necrosis of the lunate bone, with a multifactorial etiology that remains not fully understood. Since its first reported association with cerebral palsy (CP), several factors have been suggested to contribute to its higher prevalence in this population. We present the case of a 17-year-old adolescent with CP and spastic-dyskinetic tetraparesis who developed left wrist pain without any history of trauma. Initial radiographs raised suspicion of lunate mild sclerosis, and magnetic resonance imaging confirmed the diagnosis of Kienböck's disease. The patient was treated with botulinum toxin injections, resulting in pain relief and functional improvement. A review of the literature supports the observation that Kienböck's disease may be more prevalent in individuals with CP than in the general population, although it is likely underdiagnosed. Conservative management, including the use of botulinum toxin A (BoNT-A), may be effective in controlling pain and preserving function. Early recognition of Kienböck's disease in this population is essential for appropriate and individualized management, taking into account each individual's functional and cognitive profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.